Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-03-14
DOI
10.3389/fimmu.2016.00091
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
- (2015) Diana Seidel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NK-92: an “off the shelf” target-specific cytotoxic cell therapeutic
- (2015) Laurent Boissel et al. CYTOTHERAPY
- NK-92 cells engineered with anti-CD33 chimeric antigen receptors (CAR) for the treatment of Acute Myeloid Leukemia (AML)
- (2015) Sarwish Rafiq et al. CYTOTHERAPY
- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
- (2015) Richard W. Childs et al. NATURE REVIEWS DRUG DISCOVERY
- Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
- (2015) David L. Hermanson et al. Frontiers in Immunology
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
- (2015) Jianfeng Han et al. Scientific Reports
- Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation
- (2014) N. N. Shah et al. BLOOD
- Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation
- (2014) Cheol-Hun Son et al. Radiation Oncology
- Are natural killer cells superior CAR drivers?
- (2014) Hans Klingemann OncoImmunology
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody
- (2013) Ge Zhang et al. IMMUNOLOGY AND CELL BIOLOGY
- CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β
- (2013) J. Jablonska et al. INTERNATIONAL JOURNAL OF CANCER
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
- (2013) David A. Knorr et al. Stem Cells Translational Medicine
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- Development, Expansion, and In vivo Monitoring of Human NK Cells from Human Embryonic Stem Cells (hESCs) and and Induced Pluripotent Stem Cells (iPSCs)
- (2013) Allison M. Bock et al. Jove-Journal of Visualized Experiments
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7
- (2012) S. S. Somanchi et al. BLOOD
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
- (2012) Natalia Lapteva et al. CYTOTHERAPY
- Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model
- (2012) B. E. Swift et al. HAEMATOLOGICA
- Combination strategies to enhance antitumor ADCC
- (2012) Holbrook E Kohrt et al. Immunotherapy
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Establishment, Characterization, and Successful Adaptive Therapy against Human Tumors of NKG Cell, a New Human NK Cell Line
- (2011) Min Cheng et al. CELL TRANSPLANTATION
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- CXCR4 and cancer
- (2010) Bungo Furusato et al. PATHOLOGY INTERNATIONAL
- Replicative potential of human natural killer cells
- (2009) Hiroyuki Fujisaki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition
- (2009) E. Ames et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
- (2009) Laurent Boissel et al. LEUKEMIA RESEARCH
- FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
- (2008) Rodney J. Taylor et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now